Aug 21, 2025 • Benzinga
SOMEWHAT-BULLISH
Critical Inflection Point in FSGS on the Horizon with Nephrologists Poised to Rapidly Adopt New Therapies, According to Spherix Global Insights
EXTON, PA, Aug. 21, 2025 ( GLOBE NEWSWIRE ) -- The treatment landscape for focal segmental glomerulosclerosis ( FSGS ) , a rare and often progressive kidney disease, is approaching a critical inflection point.
Aug 07, 2025 • Zacks Commentary
SOMEWHAT-BULLISH
MIRM Stock Up on Q2 Earnings and Revenue Beat, Raised 2025 View
Mirum surges after second-quarter earnings and revenues top estimates, driven by Livmarli growth and a raised 2025 outlook.
Aug 07, 2025 • Motley Fool
SOMEWHAT-BULLISH
Ligand ( LGND ) Q2 Revenue Jumps 15%
Ligand Pharmaceuticals ( NASDAQ:LGND ) , a biopharma company known for earning royalties from a broad portfolio of drugs, announced results for the second quarter of 2025 on August 7, 2025. The company exceeded analyst estimates with non-GAAP EPS of $1.60 ( consensus: $1.42 ) and reported revenue ...
Aug 07, 2025 • GlobeNewswire
SOMEWHAT-BULLISH
Ligand Reports Second Quarter 2025 Financial Results and Raises Guidance
Second quarter performance driven by strong portfolio royalty revenue growth of 57% 2025 full year revenue guidance increased to $200 million - $225 million ( previously $180 million - $200 million ) and adjusted earnings per diluted share1 increased to $6.70 - $7.00 ( previously $6.00 - $6.25 )
Aug 06, 2025 • Zacks Commentary
NEUTRAL
Travere Therapeutics ( TVTX ) Reports Q2 Loss, Tops Revenue Estimates
Travere (TVTX) delivered earnings and revenue surprises of +50.00% and +17.44%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Jul 31, 2025 • Zacks Commentary
NEUTRAL
PTC Therapeutics ( PTCT ) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release
PTC Therapeutics (PTCT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.